Antares Pharma, Inc. (AIS) Announces Issuance of New U.S. Patent Covering LibiGel®
11/29/2011 10:34:53 AM
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NYSE Amex: AIS), a pharmaceutical company focused on self-injection pharmaceutical products and topical gel-based medicines, today announced that the U.S. Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,067,399, titled “Methods and Apparatus for Transdermal or Transmucosal Application of Testosterone.” The patent covers a method for treating hypoactive sexual desire disorder (HSDD) or female sexual dysfunction (FSD) by alleviating clinical symptoms of hormonal disorders related to HSDD and FSD through the convenient administration of a specially designed transdermal or transmucosal formulation. The method may be used to treat menopausal females, including surgically menopausal and naturally menopausal females, as well as pre-menopausal females with low testosterone levels. The patent covers the formulation of LibiGel®, a product which is currently under development by its partner, BioSante Pharmaceuticals, Inc. The patent is expected to provide protection until December, 2028.